Despite an expanded indication from the FDA and lower prices, patient access to these cholesterol-lowering medications remains a significant issue.

For this update to be finalized, the American Medical Association had to determine FFR_CT Analysis met certain requirements in terms of its overall impact on patient care. John Farquhar, CEO of HeartFlow, described the news as "a win for everyone involved, most notably patients." 

"It’s clear to me that urgent intervention is long overdue," one cardiologist said in a statement. 

U.S. News has shared its annual ranking of the best diets for a person's heart. Weight Watchers, Jenny Craig and Noom are out in 2024, replaced by three different options that prioritize plant-based foods. 

The company's trademark offering has now been used to evaluate one quarter of a million patients. 

Revisit some of the year's biggest trends in the diagnosis, treatment and prevention of cardiovascular disease. 

A hybrid approach may increase the risk of certain adverse events, according to a new meta-analysis focused on long-term outcomes. 

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.